GlassScriptPhysician profile
Charla C Spencer
NPI 1700851193
$258.22
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2021: $53.00 · 2022: $12.86.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.91 | 2019 | |
| Avanos Medical | $65.86 | 2021-2022 | |
| Pfizer INC. | $24.60 | 2019 | |
| Duchesnay USA Incorporated | $23.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.12 | 2019 | |
| Therapeuticsmd, INC. | $14.76 | 2019 | |
| Smith+Nephew, INC. | $13.07 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charla Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.